Marcy l'Étoile, December 14, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2020.
- Full-year 2020 net sales are now expected to be around 18% at constant exchange rates and scope of consolidation and contributive operating income before non-recurring items about €600 million.
- As a reminder, this 2020 exceptional performance is not projectable beyond 2020.
Download
- Filename
- biomerieux_pr_outlook_2020_vf.pdf
- Size
- 166 KB
- Format
- application/pdf